Adela
FOSTER CITY, CA, United States · Biotechnology · 27 employees
Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre. Adela is initially planning to develop the technolog
Funding history
- Funding Round — $5.0M — Apr 2026
- Funding Round — $25.4M — Jul 2025
- Funding Round — $48.5M — Jul 2024
- Series seed — $1.2M — Feb 2024
- Series seed — $3.3M — Feb 2024
Recent signals
- Apr 23, 2026: Raised $5.0M
- Jul 08, 2025: Raised $25.4M
- Jul 29, 2024: Raised $48.5M
- Feb 14, 2024: Raised $1.2M in Series seed
- Feb 14, 2024: Raised $3.3M in Series seed
- Dec 14, 2023: Adela Appoints Precision Medicine Veteran Lisa Alderson as CEO
- Sep 25, 2023: Raised $48.0M
- Aug 11, 2023: Raised $48.5M
See plans & pricing → Track Adela ’s funding, hiring, and signals — with verified contacts — on Fundz.